IMAC Holdings BioFirma subsidiary earns FDA registered status

Written by Alan Condon | August 14, 2019 | Print  |

Biofirma, a subsidiary of IMAC Holdings, received "registered" status by the FDA.

Three things to know:

1. The registration allows BioFirma to package, process, store, label and distribute human cells and tissue.

2. IMAC began using BioFirma's NeoCyte regenerative medicine products in its rehabilitation clinics.

3. BioFirma now sells amniotic fluid exosomes to physicians in the U.S. and reported $80,000 from the product's sales during the second quarter of 2019.

More articles on biologics:
Misonix ultrasonic device earns CE Mark approval — 4 insights
Laser Spine Institute co-founders now owe ex-business partner $300M+, judge rules
Academic panel to define best practices for outpatient stem cell procedure



© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months